(A) The incidence of OME in the VA group compared to the non-VA group. (B) The rate of tympanostomy tube insertion in the VA group and non-VA group. by Miki Kashiwagi (21439684)

The number, age, and weight of the patients with cleft lip and palate in the velar adhesion VA group and non-VA group. by Miki Kashiwagi (21439684)

The cleft width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

The dental arch length at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

The alveolar width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

The dental arch width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Sensitivity analysis. by Jiuming Li (11711375)

“…A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”

Characteristics of participants. by Jiuming Li (11711375)

“…A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”

Participant Flowchart. by Jiuming Li (11711375)

“…A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”

Stratified analyses. by Jiuming Li (11711375)

“…A significant decrease in exclusive breastfeeding rate was observed in the prolonged TTP group compared to the short TTP group (OR=0.46, 95% CI: 0.27–0.74). …”

The study flowchart. by Yuko Noda (20396439)

“…There was no significant difference in non-HDL-C levels in the long-term groups or at 1 year. …”

Overview of annotated metabolites. by Yunfei Xu (3156420)

“…<div><p>Tea ranks among the top three most beloved non-alcoholic beverages worldwide and boasts significant economic and health benefits. …”

Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”